Compare · LSTA vs PGNY
LSTA vs PGNY
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Progyny Inc. (PGNY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and PGNY operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- PGNY is the larger of the two at $1.98B, about 126.4x LSTA ($15.7M).
- Over the past year, LSTA is down 27.3% and PGNY is up 16.8% - PGNY leads by 44.1 points.
- PGNY has been more active in the news (6 items in the past 4 weeks vs 3 for LSTA).
- PGNY has more recent analyst coverage (25 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Progyny Inc.
- Price
- $1.80+1.12%
- $26.45+2.32%
- Market cap
- $15.7M
- $1.98B
- 1M return
- +55.17%
- -14.03%
- 1Y return
- -27.27%
- +16.81%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 3
- 6
- Recent ratings
- 0
- 25
Progyny Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Provides Update Following Termination of Merger Agreement
- Lisata Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update, Other Events
- Lisata Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- Amendment: SEC Form SC 14D9/A filed by Lisata Therapeutics Inc.
- SEC Form SC 14D9 filed by Lisata Therapeutics Inc.
Latest PGNY
- Wells Fargo initiated coverage on Progyny with a new price target
- Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
- SEC Form 10-Q filed by Progyny Inc.
- Progyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Progyny, Inc. Announces Second Quarter 2026 Results
- Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.
- Progyny downgraded by Barclays with a new price target
- Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
- Chief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation
- Chief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation